The document discusses breast cancer, including that it is an uncontrolled growth of breast cells, mainly ductal or lobular cancer. It explains risk factors that are beyond control like age or family history, and factors that are in control like weight, activity, and alcohol. Various treatments are discussed like PARP inhibitors, common side effects, and current clinical trials for drugs and biological therapies.

1. B
R
E
A
BREAST CANCER IS AN UNCONTROLLED S
GROWTH OF BREAST CELL T
MAINLY TWO TYPES C
 DUCTAL CANCER (85-90%) A
 LOBULAR CANCER ( almost 8%) N
C
MOST FREQUENT CANCER AMONG WOMEN AND 2nd E
RANK IN WORLD
R

2. B
Breast profile:
R
A Ducts
B Lobules
E
C Dilated section of duct A
to hold milk
D Nipple S
E Fat
F Pectoralis major T
muscle
G Chest wall/rib cage
Enlargement C
A Normal duct cells
B Basement membrane A
N
C Lumen (center of duct)
C
E
R

3. RISK FACTOR- B
R
• AGE E
BEYOND • FAMILY HISTORY A
• MEDICAL HISTORY
CONTROL S
T
• WEIGHT
• PHYSICAL ACTIVITY C
IN CONTROL • ALCOHOL A
CONSUMPTION
N
C
E
INCIDENCE INCREASED WITH AGE R

4. E
TURNIN B
G
REDNES
S OR INWAR SWELLI R
NG OF
THICKNI D
ALL OR E
NG OF
THE
PART OF
BREAST
A
NIPPLE
SYMPTOMES
S
T
LUMP IN SKIN
THE IRRITATION
UNDERAR
M AREA
OR
DIMPLING
C
BREAST
PAIN A
NIPPLE N
PAIN
C
E
EARLY BREST CANCER MAY NOT HAVE SYMPTOMS
R

5. B
R
E
A
S
T
C
A
N
C
OPTIONS:Treatment choices for the person with cancer depend
on the stage of the tumor, that is, if it has spread and how far
E
R

6.  PARP - [poly (ADP-ribose) polymer] inhibitor B
R
E
It is a group of pharmacological inhibitor of the enzyme PARP
A
OLAPARIB M.O.A S
 it is a chemotherrapeutic agent T
 kills cells that divides rapidly
 Patient with BRCA 1 and BRCA 2 mutation are also In risk of devloping C
breast cancer
A
 they are often resistance other form of breast cancer treatment
N
 so it increases the reliance on PARP torepair their DNA. C
 so the PARP inhibitor significantly benefits in patient whose cancers are E
Susceptible to treatment.
R

7. B
R
E
FATIQUE A
SOMNOLENCE S
NEUSEA T
LOSS OF APPETIDE
THROMBOCYTOPENIA
C
A
N
C
E
R

8. B
R
E
Condition Intervantion Phase A
S
Metastatic Breast
Cancer
Drug: Lapatinib
Biological:Trastuzumab
Phase III (GSK) T
Breast cancer Drug:carboplatin Phase III (university of C
Drug:Docetaxel california, los angeles)
Biological: Trastuzumab A
N
C
E
R

9. B
R
condition intervantion phase E
Ovarian Cancer Drug: cediranib Phase I (Dana farber A
cancer institute)
S
Breast Cancer Drug: olaparib Phase II(Dana farber
cancer institute
T
-------------- ( GSK)
Breast cancer Drug:Anti-erbB2 C
A
N
C
E
R